Faron Pharmaceuticals Oy New Application Accepted by Finnish Patent Office (8069N)
31 October 2016 - 6:00PM
UK Regulatory
TIDMFARN
RNS Number : 8069N
Faron Pharmaceuticals Oy
31 October 2016
Faron Pharmaceuticals Oy
("Faron" or the "Company")
New Patent Application Accepted by Finnish Patent Office
Protect the intravenous use of interferon-beta in a novel
formulation
TURKU - FINLAND, 31 October 2016 - Faron Pharmaceuticals Ltd
("Faron") (LON: FARN), the clinical stage biopharmaceutical
company, is pleased to announce that its patent application to
protect the intravenous use of interferon-beta (IFN-beta) in a
novel formulation has been accepted by the Finnish patent office.
The allowed claims cover single intravenous dose of IFN-beta at the
range of 2-15 micrograms in a formulation that allows a precise
dosing of IFN-beta. This formulation is being used in both on-going
pivotal Traumakine(R) trials in Europe and Japan for acute
respiratory distress syndrome ("ARDS") and will be the drug for
which Faron is targeting approval in various territories for the
treatment of ARDS and other vascular dysfunctions.
ARDS is a severe orphan disease with a reported mortality rate
of approximately 30-45%, for which there is currently no approved
pharmacological treatment. It is characterised by widespread
capillary leakage and inflammation in the lungs, most often as a
result of pneumonia (e.g. following a pandemic influenza), sepsis,
or significant trauma. An earlier Phase I/II trial conducted in the
UK and published in The Lancet Respiratory Medicine, (Bellingan et
al. 2014: 2: 98-107), showed a decline in the odds of all-cause
mortality at day 28 of 81%. Faron has developed the first
intravenous formulation of IFN-beta to enable treatment of vascular
leakage in lungs and other central organs. The allowed claims cover
this use but are not limited to ARDS.
Dr Markku Jalkanen, CEO of Faron said: "We are delighted that
the patent claims for the intravenous use of IFN-beta in vascular
dysfunctions have been accepted as they enable us to build a strong
global proprietary position for Traumakine(R). We have already
granted patents for INF-beta in ischemic conditions in many
countries, and these additional claims significantly extend
protection for Traumakine(R) as a drug to treat life threatening
conditions like acute lung injuries up to 2036-37. Faron plans to
file application to the US patent office with same scope of
protection. Furthermore, in spring 2017 we will file the
international PCT to initiate the patenting process in other
countries too."
The information contained within this announcement constitutes
inside information stipulated under the Market Abuse Regulation
(EU) No. 596/2014.
For more information please contact:
Faron Pharmaceuticals Ltd
Katja Wallenlind
Phone +358 (50) 577 4807
E-mail: katja.wallenlind@faronpharmaceuticals.com
Hume Brophy, PR
Mary Clark, Eva Haas, Hollie Vile
Phone: +44 207 862 6390
E-mail: faron@humebrophy.com
Cairn Financial Advisers LLP, Nominated Adviser
Emma Earl, Tony Rawlinson, Rebecca Anderson
Phone: +44 207 213 0880
Panmure Gordon (UK) Limited, Joint Broker
Freddy Crossley, Duncan Monteith (Corporate Finance)
Tom Salvesen (Corporate Broking)
Phone: +44 207 886 2500
Whitman Howard Limited, Nominated Broker
Ranald McGregor-Smith, Francis North
Phone: +44 207 659 1234
About Faron Pharmaceuticals Ltd
Faron is a clinical stage biopharmaceutical company developing
novel treatments for medical conditions with significant unmet
needs. The Company currently has a pipeline focusing on acute organ
traumas, cancer immunotherapy and vascular damage. The pipeline is
built on Faron's scientific knowledge and control of the
endothelial barrier, the membrane of cells lining blood and
lymphatic vessels to separate blood content from tissues. The
Company's lead candidate Traumakine(R) is in development for the
treatment of Acute Respiratory Distress Syndrome ("ARDS"), a rare,
severe, life-threatening medical condition characterised by
widespread inflammation in the lungs. Traumakine is currently in
pan-European (INTEREST) and Japanese pivotal Phase III studies.
Additionally, Faron is developing Clevegen(R) a ground breaking
pre-clinical anti-Clever-1 antibody. Clevegen has the ability to
convert the immune environment around a tumour from being immune
suppressive to immune stimulating. This novel macrophage-directed
immuno-oncology approach is called Tumour Immunity Enabling
Technology ("TIET") and can be used alone or in combination with
other immune checkpoint molecules for the treatment of cancer
patients. New application opportunities related to TIET cover
chronic infections and inefficient vaccination. Based in Turku,
Finland, Faron Pharmaceuticals is listed on AIM under the ticker
'FARN'. Further information is available at
www.faronpharmaceuticals.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCLBLLXQBFBFBF
(END) Dow Jones Newswires
October 31, 2016 03:00 ET (07:00 GMT)
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From Apr 2024 to May 2024
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From May 2023 to May 2024